Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refr

Go back to Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refr
Bristol-Myers Squibb (NYSE: BMY) Delayed: 60.81 -0.87 (1.41%)
Previous Close $61.68    52 Week High $77.12 
Open $61.50    52 Week Low $49.03 
Day High $61.81    P/E 39.49 
Day Low $60.72    EPS $1.54 
Volume 2,404,763